DrugInfoSys

Telmisartan

Drug #1657

A newer angiotensin-II receptor antagonist, a useful alternative for the patient who has to discontinue ACE inhibitor because of persistent cough. It is used in the treatment of hypertension.

← Previous drugNext drug →

Primary Characteristics

It is of Synthetic origin.

It belongs to Angiotensin-II receptor antagonist pharmacological group on the basis of mechanism of action. It is also classified under Antihypertensive Agents .

Non-proprietary name: Telmisartan.

Molecular structure of Telmisartan

Pharmacokinetics

None recorded.

Advertisement

Indications

Telmisartan is primarily indicated in conditions like Hypertension.

Telmisartan is also indicated for secondary conditions like Diabetic nephropathy, Heart failure.

Contraindications

Telmisartan is contraindicated in conditions like Pregnancy, Breast feeding, Adjunct in treatment of opioid dependance, Dry or painful cough.

Dosage

Telmisartan's dosage details are as follows:

DoseSingle DoseFrequencyRouteInstructions
Adult Dosage
40 mg40 mgEvery 24hPOBut 20 mg may be sufficient , increased if necessary after at least 4 weeks, to max. 80 mg once daily.
Paediatric Dosage (20kg)
No data.
Neonatal Dosage (3kg)
No data.

Drug Interactions

1 interaction
Moderate2 interactions

Always consult your physician for the change of dose regimen or an alternative drug of choice that may strictly be required.

Side Effects

Telmisartan in overdosage may give rise to further complications which include Dyspnea, Blood disorders .

Telmisartan is known to cause more or less tolerable side effects which are usually transient. These include Anxiety, Arthralgia, Back pain, Eczema, Flatulence, Gastrointestinal disturbances, Hypotension , Increased sweating, Leg cramps, Myalgia, Pharyngitis, Pruritus , Rashes , Sinusitis .

Warnings / Precautions

Hepatic impairment-avoid if severe; active gastric or duodenal ulceration or other GI disease (Increased risk of gastro-intestinal bleeding); use with caution in renal artery stenosis, aortic or mitral valve stenosis and in obstructive hypertrophic cardiomyopathy.Monitor plasma-potassium concentration, particularly in elderly and in patients with renal impairment; lower initial doses may be appropriate in these patients.

Interference in Pathology

Telmisartan may interfere in the diagnosis of Increased level of Blood urea nitrogen (BUN) concentrations, Increased in serum creatinin, Elevated liver enzymes.

Available Brands

Click on a strength to view available brands.

Single Ingredient

Tabs
20 mg40 mg50 mg80 mg

Multi-Ingredient Combinations

Tabs
4 mg40 mg80 mg

Drug Classification

  1. 1.12.3.4 — Angiotensin II receptor anatgonists

Manufacturers